Global Perspectives and Clinical Resources to Guide Treatment Decisions and Management of Adverse Events With BTK Inhibitor Therapy in CLL

Deepen your understanding of the optimal use of BTK inhibitors in CLL, including treatment strategies and managing potential AEs associated with these agents, through an expert-written text module with accompanying slides, a ClinicalThought commentary, and 2 interactive decision support tools—1 to support treatment decisions in CLL and another to support BTK inhibitor AE management.

Share

Program Content

Activities

IDST for BTKi AEs
Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: January 07, 2025

Expires: January 06, 2026

CLL Global IDST
Interactive Tool With Expert Guidance for the Treatment of CLL: An International Perspective
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: March 25, 2025

Expires: September 24, 2025

Activities

CLL BTK Inhibitor Tx and AE Guide
Global Perspectives and Clinical Resources to Guide Treatment Decisions and Management of Adverse Events With BTK Inhibitor Therapy in CLL 
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

Activities

CLL BTK Inhibitor Tx and AE Guide
Global Guide to BTK Inhibitor Treatment Decisions and AE Management in CLL 
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

Activities

CLL Treatment
My Thoughts on the Current and Emerging Treatment of CLL/SLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2024

Expires: October 24, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC 

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca